Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Search
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada approves first treatment option for generalized pustular psoriasis flares in adults
- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Irene Anindita
Irene Anindita is a Multichannel Manager for Cardiovascular and Metabolism Team in Amsterdam, the Netherlands, and really loves the vibe.
Equine asthma: Recognizing and managing respiratory issues in horses
Equine asthma: Recognizing and managing respiratory issues in horses
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Aging seniors to reap long-term health benefits from Edmonton-based artificial intelligence project
Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Vaccines
Science and Innovation - Animal Health Innovation - Vaccines
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Optimizing oxygen needs for people living with Interstitial Lung Disease
Optimizing oxygen needs for people living with Interstitial Lung Disease
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease
Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease
Lung Cancer
Lung Cancer
Livestock
Livestock
Hypertension
Hypertension
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Multidisciplinary care reduces hospitalizations for chronic obstructive pulmonary disease (COPD) patients
Multidisciplinary care reduces hospitalizations for chronic obstructive pulmonary disease (COPD) patients
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease